172 related articles for article (PubMed ID: 35099823)
1. Loss of STING expression is prognostic in non-small cell lung cancer.
Lohinai Z; Dora D; Caldwell C; Rivard CJ; Suda K; Yu H; Rivalland G; Ellison K; Rozeboom L; Dziadziuszko R; Mitchell P; John T; Millan IS; Ren S; Hirsch FR
J Surg Oncol; 2022 May; 125(6):1042-1052. PubMed ID: 35099823
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
Yang KS; Xu CQ; Lv J
Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
[TBL] [Abstract][Full Text] [Related]
3. Increased activation of cGAS-STING pathway enhances radiosensitivity of non-small cell lung cancer cells.
Xue A; Shang Y; Jiao P; Zhang S; Zhu C; He X; Feng G; Fan S
Thorac Cancer; 2022 May; 13(9):1361-1368. PubMed ID: 35429143
[TBL] [Abstract][Full Text] [Related]
4. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer.
Gao Y; Zhang N; Zeng Z; Wu Q; Jiang X; Li S; Sun W; Zhang J; Li Y; Li J; He F; Huang Z; Zhang J; Gong Y; Xie C
Clin Transl Med; 2022 Apr; 12(4):e792. PubMed ID: 35415876
[TBL] [Abstract][Full Text] [Related]
5. An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango.
Hao F
Clin Transl Oncol; 2022 Sep; 24(9):1661-1672. PubMed ID: 35377059
[TBL] [Abstract][Full Text] [Related]
6. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer.
Yan X; Yao C; Fang C; Han M; Gong C; Hu D; Shen W; Wang L; Li S; Zhu S
Int J Biol Sci; 2022; 18(2):585-598. PubMed ID: 35002511
[No Abstract] [Full Text] [Related]
7. Entanglement of Methylation Changes and cGAS-STING Signaling in Non-Small-Cell Lung Cancer.
Hao F
Comb Chem High Throughput Screen; 2023; 26(1):224-235. PubMed ID: 35585823
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
10.
He XU; Yu Y; Zhang X; Gao C; Wang H; Liu C
Cancer Genomics Proteomics; 2023; 20(5):476-486. PubMed ID: 37643778
[TBL] [Abstract][Full Text] [Related]
11. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma.
Qi Z; Yan F; Chen D; Xing W; Li Q; Zeng W; Bi B; Xie J
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33006365
[TBL] [Abstract][Full Text] [Related]
12. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
[TBL] [Abstract][Full Text] [Related]
13. cGAS-STING Activation in the Tumor Microenvironment and Its Role in Cancer Immunity.
Pépin G; Gantier MP
Adv Exp Med Biol; 2017; 1024():175-194. PubMed ID: 28921470
[TBL] [Abstract][Full Text] [Related]
14. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
17. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
[TBL] [Abstract][Full Text] [Related]
18. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
Cronin-Fenton D; Dalvi T; Movva N; Pedersen L; Hansen H; Fryzek J; Hedgeman E; Mellemgaard A; Rasmussen TR; Shire N; Hamilton-Dutoit S; Nørgaard M
Sci Rep; 2021 Aug; 11(1):16892. PubMed ID: 34413420
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
[Next] [New Search]
